CD8A and neoplasm: The lack of CD8+ T cells in the tumor site after treatment can in part explain relapse to anti-PD1 therapy. circFAT1 can promote an immunosuppressive TME in HNSCC, and its block enhances immune therapies target PD-1 also improving CD8+ cells infiltration.